Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Xencor to Present at Upcoming Investor Conferences


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate at three upcoming conferences:

  • Jefferies Virtual London Healthcare Conference
    Conference Dates: November 17-19, 2020
    Presentation Date:
    Thursday, November 19, 2020
    Presentation Time: 5:00 p.m. GMT / 9:00 a.m. PST
  • SVB Leerink Oncology Day
    Conference Date: Thursday, November 19, 2020
  • Piper Sandler 32nd Annual Virtual Healthcare Conference
    Conference Dates: November 30 - December 3, 2020
    Presentation Available: Monday, November 23, 2020

Webcasts of the Jefferies and Piper Sandler presentations will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. A replay of the live Jefferies presentation will be posted on the Xencor website approximately one hour after the live event. Both presentations will be available for at least 30 days.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. Currently, 18 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112006032/en/

Xencor Inc. Stock

€19.40
-1.020%
We can see a decrease in the price for Xencor Inc.. Compared to yesterday it has lost -€0.200 (-1.020%).
With 14 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 31 € there is a hugely positive potential of 59.79% for Xencor Inc. compared to the current price of 19.4 €.
Like: 0
Share
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Legal notice

Comments